Paul-Ehrlich-Institut

Coronavirus and COVID-19

Research Work

Highlights

Measure What Fuses – Tissue Damage through Cell Fusion in COVID-19 and the Role of the Spike Protein
COVID-19 Therapy with Convalescent Plasma – Tests for the Identification of Suitable Donor Plasma
Measles Virus Vaccination-based-SARS-CoV-2 Vaccine induces Immune Response in Mice and Hamsters
COVID-19: How is Severity of the Disease Related to Antibody Response?
More Flexible than Expected - New Findings on the Spike Protein of SARS-CoV-2
3D Mapping of Viruses by Electron Microscopy
SARS-CoV-2 Immunogenity at the Crossroads

Publications

Please note: Authors from the Paul-Ehrlich-Institut are highlighted in bold. For online abstracts or full text publications, please follow the links.

Meyer H (2021): COVID-19-Impfstoffe – Übersicht über in Europa zugelassene oder im Zulassungsprozess befindliche Impfstofftypen.
Bulletin zur Arzneimittelsicherheit 12: 20-22.
Text

Pfaar O, Mahler V (2021): Allergic reactions to COVID-19 -vaccinations - unveiling the secret(s).
Allergy Jan 12 [Epub ahead of print].
Online-Abstract

Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, Jutel M, Nadeau KC, Palomares O, Rabin RL, Riggioni C, Vieths S, Agache T, Shamji MH (2021): EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines.
Allergy Jan 16 [Epub ahead of print].
Online-Abstract

Theuerkauf SA, Michels A, Riechert V, Maier TJ, Flory E, Cichutek K, Buchholz CJ (2021): Quantitative Assays Reveal Cell Fusion at Minimal Levels of SARS-CoV-2 Spike Protein and Fusion-from-Without.
iScience 24: 102170.
Online-Abstract

Weisser K, Kling K, Huth C, Keller-Stanislawski B, Mahler V (2021): Was ist bei positiver Allergieanamnese vor einer Impfung gegen COVID-19 zu beachten?.
Bulletin zur Arzneimittelsicherheit 12: 23-26.
Text

Berg P, Heiden M, Müller S, Oberle D, Funk M, Keller-Stanislawski B (2020): SARS-CoV-2-Infektionen und Sicherheit von Blut und Blutkomponenten.
Bulletin zur Arzneimittelsicherheit 11: 17-19.
Text

Börger V, Weiss DJ, Anderson JD, Borràs FE, Bussolati B, Carter DRF, Dominici M, Falcón-Pérez JM, Gimona M, Hill AF, Hoffman AM, de Kleijn D, Levine BL, Lim R, Lötvall J, Mitsialis A, Monguió-Tortajada M, Muraca M, Nieuwland R, Nowocin A, O'Driscoll L, Ortiz LA, Phinney DG, Reischl I, Rohde E, Sanzenbacher R, Théry C, Wei ST, Witwer KW, Lim SK, Giebel B (2020): ISEV and ISCT Statement on EVs From MSCs and Other Cells: Considerations for Potential Therapeutic Agents to Suppress COVID-19.
Cytotherapy 22: 482-485.
Online-Abstract

Corman VM, Rabenau HF, Adams O, Oberle D, Funk MB, Keller-Stanislawski B, Timm J, Drosten C, Ciesek S (2020): SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission.
Transfusion 60: 1119-1122.
Online-Abstract

Henss L, Scholz T, von Rhein C, Wieters I, Borgans F, Eberhardt FJ, Zacharowski K, Ciesek S, Rohde G, Vehreschild M, Stephan C, Wolf T, Hofmann-Winkler H, Scheiblauer H, Schnierle BS (2020): Analysis of humoral immune responses in SARS-CoV-2 infected patients.
J Infect Dis Oct 31 [Epub ahead of print].
Online-Abstract

Hörner C, Schürmann C, Auste A, Ebenig A, Muraleedharan S, Dinnon KH, Scholz T, Herrmann M, Schnierle B, Baric RS, Mühlebach MD (2020): A Highly Immunogenic Measles Virus-based Th1-biased COVID-19 Vaccine.
PNAS 117: 32657-32666.
Text

Karamloo F, König R (2020): SARS-CoV-2 immunogenicity at the crossroads.
Allergy 75: 1822-1824.
Online-Abstract

Kochhar S, Excler JL, Kim D, Robertson JS, Fast PE, Condit RC, Drew S, Wood D, Gurwith M, Klug B, Whelan M, Khuri-Bulos N, Mallett Moore T, Smith ER, Chen RT, Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) (2020): The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
Vaccine 38: 6184-6189.
Online-Abstract

Kochhar S, Kim D, Excler JL, Condit RC, Robertson JS, Drew S, Whelan M, Wood D, Fast PE, Gurwith M, Klug B, Khuri-Bulos N, Smith ER, Chen RT, Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) (2020): The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
Vaccine 38: 5734-5739.
Text

Oberle D, Mentzer D, Weber G (2020): Befragung zur Verträglichkeit der Impfstoffe gegen das neue Coronavirus (SARS-CoV-2) mittels Smartphone-App SafeVac 2.0.
Bulletin zur Arzneimittelsicherheit 11: 27-31.
Text

Schramm W, Seitz R, Gürtler L (2020): COVID-19-associated coagulopathy - Hypothesis: Are Children protected due to enhanced thrombin inhibition by higher α2 -Macroglobulin (α2-M)?.
Thromb Haemost 18: 2416-2418.
Online-Abstract

Seitz R, Gürtler L, Schramm W (2020): Thromboinflammation in COVID-19: Can α2-Macroglobulin Help to Control the Fire?.
J Thromb Haemost Nov 23 [Epub ahead of print].
Online-Abstract

Seitz R, Schramm W (2020): DIC in COVID-19: Implications for Prognosis and Treatment?.
J Thromb Haemost 18: 1798-1799.
Online-Abstract

Turonova B, Sikora M, Schürmann C, Hagen WJH, Welsch S, Blanc FEC, Bülow von S, Gecht M, Bagola K, Hörner C, van Zandbergen G, Mosalaganti S, Schwarz A, Covino R, Mühlebach MD, Hummer G, Krijnse Locker J, Beck M (2020): In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges.
Science 370: 203-208.
Text

von Rhein C, Scholz T, Henss L, Kronstein-Wiedemann R, Schwarz T, Rodionov RN, Corman VM, Tonn T, Schnierle BS (2020): Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma.
J Virol Methods Dec 1 [Epub ahead of print].
Text

Content

  1. Role of the Paul-Ehrlich-Institut
  2. COVID-19 Vaccines
  3. FAQ Coronavirus
  4. Biomedicines
  5. Safety of COVID-19 Vaccines
  6. Research Work
  7. SARS-CoV-2 Test Systems